A Phase Ib, Randomized, Double-Blind, Placebo-Controlled Trial in Asian Genotype 1 Chronic HCV-Infected Subjects to Determine the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Repeated Doses of JNJ-47910382 Given in Different Doses and Dose Regimens

Trial Profile

A Phase Ib, Randomized, Double-Blind, Placebo-Controlled Trial in Asian Genotype 1 Chronic HCV-Infected Subjects to Determine the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Repeated Doses of JNJ-47910382 Given in Different Doses and Dose Regimens

Recruiting
Phase of Trial: Phase I

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs JNJ 47910382 (Primary)
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Sponsors Janssen R&D Ireland
  • Most Recent Events

    • 16 Apr 2014 Planned End Date changed from 1 Apr 2015 to 1 Dec 2014 as reported by ClinicalTrials.gov record.
    • 10 Feb 2014 The number of treatment panels changed from 4 to 3; dosing regimen changed from od and bid to od only as reported by ClinicalTrials.gov record.
    • 10 Feb 2014 Planned End Date changed from 1 Mar 2014 to 1 Apr 2015 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top